Dea No. 9143 en es it fr

Dea No. 9143 Brand names, Dea No. 9143 Analogs

Dea No. 9143 Brand Names Mixture

  • Combunox
  • ENDOCET
  • PERCOCET
  • ENDODAN
  • Percodan-Demi (Acetylsalicylic Acid + Oxycodone Hydrochloride)
  • Pms-Oxycodone - Acetaminophen (Acetaminophen + Oxycodone (Oxycodone Hydrochloride))
  • Rivacocet (Acetaminophen + Oxycodone (Oxycodone Hydrochloride))
  • Roxicet Tab (Acetaminophen + Oxycodone Hydrochloride)

Dea No. 9143 Chemical_Formula

C18H21NO4

Dea No. 9143 RX_link

http://www.rxlist.com/cgi/generic2/oxyco.htm

Dea No. 9143 fda sheet

Dea_No._9143 FDA

Dea No. 9143 msds (material safety sheet)

Dea_No._9143 MSDS

Dea No. 9143 Synthesis Reference

Small, Lutz, "Chemistry of the Opium Alkaloids", Suppl.No.103 (1932)

Dea No. 9143 Molecular Weight

315.364 g/mol

Dea No. 9143 Melting Point

218-220 oC

Dea No. 9143 H2O Solubility

100 mg/ml

Dea No. 9143 State

Solid

Dea No. 9143 LogP

0.993

Dea No. 9143 Dosage Forms

Tablet; Suppository

Dea No. 9143 Indication

For the treatment of diarrhoea, pulmonary oedema; For the relief of moderate to moderately severe pain

Dea No. 9143 Pharmacology

Oxycodone, a semisynthetic opiate agonist derived from the opioid alkaloid, thebaine, is similar to other phenanthrene derivatives such as hydrocodone and morphine. Oxycodone is available in combination with aspirin or acetaminophen to control pain and restless leg and Tourette syndromes.

Dea No. 9143 Absorption

well absorbed from OxyContin® tablets with an oral bioavailability of 60% to 87%

Dea No. 9143 side effects and Toxicity

respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, bradycardia, hypotension, and death.

Dea No. 9143 Patient Information

WARNINGS

Drug Dependence: Oxycodone can produce drug dependence of the morphine type, and therefore, has the potential for being abused. Psychic dependence, physical dependence and tolerance may develop upon repeated administration of this drug, and it should be prescribed and administered with the same degree of caution appropriate to the use of other oral narcotic-containing medications. Like other narcotic-containing medications, this drug is subject to the Federal Controlled Substances Act.

Usage in Ambulatory Patients: Oxycodone may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. The patient using this drug should be cautioned accordingly.

Interaction with Other Central Nervous System Depressants: Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics or other CNS depressants (including alcohol) concomitantly with oxycodone hydrochloride may exhibit an additive CNS depression. When such combined therapy is contemplated, the dose of one or both agents should be reduced.

Usage in Pregnancy: Safe use in pregnancy has not been established relative to possible adverse effects on fetal development. Therefore, this drug should not be used in pregnant women unless, in the judgment of the physician, the potential benefits outweigh the possible hazards.

Usage in Children: This drug should not be administered to children.

PRECAUTIONS

Head Injury and Increased Intracranial Pressure: The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions or a pre-existing increase in intracranial pressure. Furthermore, narcotics produce adverse reactions which may obscure the clinical course of patients with head injuries.

Acute Abdominal Conditions: The administration of this drug or other narcotics may obscure the diagnosis or clinical course in patients with acute abdominal conditions.

Special Risk Patients: This drug should be given with caution to certain patients such as the elderly, or debilitated, and those with severe impairment of hepatic or renal function, hypothyroidism, Addison's disease and prostatic hypertrophy or urethral stricture.

Dea No. 9143 Organisms Affected

Humans and other mammals